Search

Degradable magnesium alloys are promising biomaterials for orthopedic applications. The aim of this study was to evaluate the potential effects on both the synovial membrane (synovialis) and the synovial fluid (synovia) of the degradation products of a MgYREZr-pin implanted in the intercondylar femoral notch in a rabbit model. Thirty-six animals were randomized into two groups (MgYREZr or Ti6Al4V alloy) of 18 animals each. Each group was then divided into three subgroups with implantation periods of 1, 4, and 12 weeks, with six animals in each subgroup. The initial inflammatory reaction caused by the surgical trauma declined after 12 weeks of implantation, and elucidated a progressive recovery of the synovial membrane. Compared with control Ti6Al4V pins, there were no significant differences between the groups. However, after 12 weeks, recovery of the synovial membrane was more advanced in the titanium group, in which 92% showed no signs of synovitis, than in the magnesium group. A cytotoxicity test with L929 cells and human osteoblasts (HOB) was also conducted, according to EN ISO 10993-5/12, and no toxic leachable products were observed after 24 h of incubation. In conclusion, the MgYREZr alloy seems to be a suitable material for intra-articular degradable implants. © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Aims: Everolimus (EVL) is a proliferation signal inhibitor (PSI), combining immunosuppressive and anti-proliferative actions. Sirolimus, the first available PSI, has been linked with impaired post-operative tissue regeneration. The incidence of delayed wound healing, wound dehiscence and lymphocoele to Month 6 after renal transplant (Tx) with MMF- and EVL-based immunosuppression is presented. Method(s): Data were pooled from four randomized, prospective, de novo renal Tx studies: the MMF arms from two 36-month, parallel group studies (B201, B251) in which patients received MMF 2g/day with standard-dose cyclosporine (CsA) and steroids, and the EVL arms of two 12-month studies (A2306, A2307) in which patients received EVL 1.5mg/day or 3.0mg/day, adjusted to target trough levels of 38 ng/mL plus low-exposure CsA and steroids (with basiliximab in A2307). Complications associated with postoperative healing from the initial surgical trauma were retrieved from the studies' adverse event (AE) databases and analyzed based on their starting date, duration and severity. Result(s): A total of 135 (2.20%) events occurred in 126 EVL recipients which were associated with post-operative wound-healing-related complications. In comparison, 96 (1.97%) wound-healing-related AEs were reported in 93 MMF-treated patients. In both groups, >=85% of these events were classified as mild or moderate. Overall, the incidence of wound-healing associated SAEs was low(Table presented). Conclusion(s): The overall incidence and severity of wound-healingassociated complications following renal Tx were comparable for MMF- and EVL-based immunosuppression. The majority of complications were mild to moderate and did not lead to study drug discontinuation.

Aims: Everolimus (EVL) is a proliferation signal inhibitor (PSI), combining immunosuppressive and anti-proliferative actions. Sirolimus, the first available PSI, has been linked with impaired post-operative tissue regeneration. The incidence of delayed wound healing, wound dehiscence and lymphocoele to Month 6 after renal transplant (Tx) with MMF- and EVL-based immunosuppression is presented. Method(s): Data were pooled from four randomized, prospective, de novo renal Tx studies: the MMF arms from two 36-month, parallel group studies (B201, B251) in which patients received MMF 2g/day with standard-dose cyclosporine (CsA) and steroids, and the EVL arms of two 12-month studies (A2306, A2307) in which patients received EVL 1.5mg/day or 3.0mg/day, adjusted to target trough levels of 38 ng/mL plus low-exposure CsA and steroids (with basiliximab in A2307). Complications associated with postoperative healing from the initial surgical trauma were retrieved from the studies' adverse event (AE) databases and analyzed based on their starting date, duration and severity. Result(s): A total of 135 (2.20%) events occurred in 126 EVL recipients which were associated with post-operative wound-healing-related complications. In comparison, 96 (1.97%) wound-healing-related AEs were reported in 93 MMF-treated patients. In both groups, >=85% of these events were classified as mild or moderate. Overall, the incidence of wound-healing associated SAEs was low(Table presented). Conclusion(s): The overall incidence and severity of wound-healingassociated complications following renal Tx were comparable for MMF- and EVL-based immunosuppression. The majority of complications were mild to moderate and did not lead to study drug discontinuation.

[No abstract available]